Comparison between Citichem India IPO and Hamps Bio IPO.
Citichem India IPO is a SME Fixed Price IPO proposed to list at BSE SME while Hamps Bio IPO is a SME Fixed Price proposed to list at BSE SME.
| Citichem India IPO | Hamps Bio IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price | Fixed Price |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Horizon Management Pvt.Ltd. | Marwadi Chandarana Intermediaries Brokers Pvt.Ltd. |
| Registrar | Kfin Technologies Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Aftertrade Broking Pvt.Ltd. | Pure Broking Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Anchor Investor | ||
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Citichem India IPO is up to ₹11.96 Cr whereas the issue size of the Hamps Bio IPO is up to ₹5.91 Cr. The final issue price of Citichem India IPO is ₹70.00 per share and of Hamps Bio IPO is ₹51.00 per share.
| Citichem India IPO | Hamps Bio IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ₹70.00 per share | ₹51.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 2000 shares | 2000 shares |
| Fresh Issue Size | 17,08,000 shares | 11,58,000 shares |
| Fresh Issue Size (Amount) | up to ₹11.96 Cr | up to ₹5.91 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 17,08,000 shares | 11,58,000 shares |
| Issue Size Total (Amount) | up to ₹11.96 Cr | up to ₹5.91 Cr |
Citichem India IPO opens on Dec 27, 2024, while Hamps Bio IPO opens on Dec 13, 2024. The closing date of Citichem India IPO and Hamps Bio IPO is Dec 31, 2024, and Dec 17, 2024, respectively.
| Citichem India IPO | Hamps Bio IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Dec 27, 2024 | Dec 13, 2024 |
| Issue Close | Dec 31, 2024 | Dec 17, 2024 |
| Basis Of Allotment (Tentative) | Jan 01, 2025 | Dec 18, 2024 |
| Initiation of Refunds (Tentative) | Jan 02, 2025 | Dec 19, 2024 |
| Credit of Share (Tentative) | Jan 02, 2025 | Dec 19, 2024 |
| Listing date (Tentative) | Jan 03, 2025 | Dec 20, 2024 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Citichem India IPO P/E ratio is 31.3, as compared to Hamps Bio IPO P/E ratio of 31.94.
| Citichem India IPO | Hamps Bio IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Citichem India Limited Financial Information (Restated)Citichem India Limited's revenue decreased by -6% and profit after tax (PAT) rose by 208% between the financial year ending with March 31, 2024 and March 31, 2023.
| Hamps Bio Limited Financial Information (Restated)Hamps Bio Limited's revenue increased by 16.41% and profit after tax (PAT) rose by 39.47% between the financial year ending with March 31, 2024 and March 31, 2023.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 83.25 | 100.00 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 61.21 | 71.99 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 31.3 | 31.94 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹47.60 Cr. | ₹22.22 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 15.42% | 21.14% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 21.47% | 18.31% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.15 | 0.31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹2.24 | ₹1.60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 15.42% | 14.84% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Citichem India IPO Retail Individual Investors (RII) are offered 8,54,000 shares while in Hamps Bio IPO retail investors are offered 8,54,000 shares. Qualified Institutional Buyers (QIB) are offered in Citichem India IPO and in Hamps Bio IPO.
| Citichem India IPO | Hamps Bio IPO | |
|---|---|---|
| Anchor Investor Reserveration | ||
| Market Maker Reserveration | 92,000 shares | 62,000 shares |
| QIB | ||
| NII | 8,54,000 shares | 5,78,000 shares |
| RII | 8,54,000 shares | 5,80,000 shares |
| Employee | ||
| Others | ||
| Total | 17,08,000 shares | 11,58,000 shares |
Citichem India IPO subscribed 414.35x in total, whereas Hamps Bio IPO subscribed 1,057.00x.
| Citichem India IPO | Hamps Bio IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | 277.88x | 758.27x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 543.18x | 1,342.04x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 414.35x | 1,057.00x |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
